CD8A and neoplasm: Building off of promising preclinical results of combination immunotherapies in murine models of solid cancers, which had shown significant synergistic effects in terms of tumor reduction and survival improvement, as well as elevated abundance and anti‐tumor activity of CD8+ T cells, compared to the corresponding monotherapies [12, 13, 14], the non‐randomized phase II trial NSGO‐OV‐UMB1/ENGOT‐OV30 was designed as a three‐arm umbrella trial for testing the clinical efficacy of several novel combinations of immunotherapeutics in patients with relapsed EOC [15].